Jumonji Domain Containing 6, Arginine Demethylase And Lysine Hydroxylase
| Inventor | Institute |
|---|---|
| Yvan Canitrot | Toulouse Tech Transfer |
| SKU: | 161710 |
|---|---|
| Product description: | Catalitically inactive JMJD6 U2OS cell line used to study the role of the JMJD6 enzyme in DNA maintenance following DNA damage |
| Alternate name: | JMJD6 KO+Mut |
| Gender: | Female |
| CRISPR: | Yes |
| Conditional: | No |
| Production details: | Gene inactivation by CRISPR-Cas9 and reintroduction of a mutant form of JMJD6 defective for its catalytic activity. Stable expression via a plasmid coding for JMJD6 mutant (H187A-D189A-H273A). |
| Receptors of note: | Insulin like growth factor |
| Parental cell line: | U2OS |
| Model description: | JMJD6 knock out using CRISPR-Cas9 and knock in of a catalytically inactive form of JMJD6 |
| Disease: | Myasthenic Syndrome |
| Cat. #: | 161710 |
|---|---|
| Tool sub type: | Continuous |
| Cancer types: | Sarcoma |
| Research Fields: | Cancer |
| Organism: | Human |
| Tissue: | Bone |
| Gender: | Female |
| Model: | Knock-Out; Knock-In |
| Morphology: | Epithelial |
| Growth properties: | Adherent |
| Cancer Types In Detail: | Osteosarcoma |
| Primary citation: | Fages et al. 2020. PLoS Genet 16(6):e e1008511. PMID: 32598339. |
| Storage conditions: | Liquid Nitrogen |
|---|---|
| Shipping conditions: | Dry ice |
| Growth medium: | DMEM medium supplemented with 10% foetal calf serum, sodium pyruvate and antibiotics (penicillin/streptomycin) |
| Temperature: | 37° C |
| Atmosphere: | 5% CO2 |
| Recommended controls: | Parental U2OS cell line, JMJD6 WT cell lines, JMJD6 deficient U2OS cell line |
| Biosafety level: | 1 |
| References: |
Fages et al. 2020. PLoS Genet 16(6):e e1008511. PMID: 32598339. |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.